Dexcom Inc (DXCM) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Dexcom Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Dexcom Inc's ROI in the second quarter of 2026? Dexcom Inc achieved a return on average invested assets (ROI) of 21.26 % in its second quarter of 2026, this is above DXCM's average return on investment of -9.59%. Dexcom Inc s investments during the 12 months ending in the second quarter of 2026 are valued at $4 billion
ROI fell compared to the first quarter of 2026, despite the net income growth of 25.71% from the first quarter of 2026.
Within the Healthcare sector 46 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 281, from total ROI ranking in the first quarter of 2026 at 286.
DexCom Faces Class Action Lawsuit: Investors Urged to Act Before October 21, 2024 DeadlineIn recent developments concerning DexCom, Inc. (NASDAQ: DXCM), a class action securities lawsuit has been filed against the diabetes management company, drawing the attention of investors and stakeholders alike. The legal firm Levi and Korsinsky, LLP, has issued a notification regarding this lawsuit, urging affected investors to consider joining the class action before the upcoming deadline of October 21, 2024.The class action arises from allegations that the company may have made false or misleading statements concerning its financial health and business operations, which, if proven, could significantly impact shareholder value. Investors impacted by these potential misstatements are encouraged to reach out to Levi and Korsinsky for more information on how to join the lawsuit.
Legal Storm Clouds Gather Over DexCom: What Investors Need to Know In recent weeks, DexCom, Inc. (NASDAQ: DXCM) has found itself embroiled in a swirl of legal challenges that have investors on edge. Prominent law firms Levi and Korsinsky, LLP and Johnson Fistel, LLP have both announced class action lawsuits against the company, prompting shareholders to take a closer look at DexCom s financial and operational health. Class Action Notifications Levi and Korsinsky s WarningOn September 25, 2024, Levi and Korsinsky, LLP issued a public notice alerting investors about a class action securities lawsuit against DexCom. The firm aims to represent shareholders who may have been adversely affected by the company s actions. Investors are urged to contact the law firm before October 21, 2024, to better understand their rights and potentially join the lawsuit.
SAN DIEGO DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, is propelling its pioneering initiative, Dexcom U, into its third season. This announcement celebrates the continuation of a program that has significantly altered the landscape for college athletes living with diabetes. Heralded by Ad Age as a Top 5 NIL (Name, Image, Likeness) partnership following its inaugural season in 2022, Dexcom U returns with an expanded roster and renewed commitment to mentorship, advocacy, and empowerment within the diabetic community. Commencing the 2024 Season with New Athlete Ambassadors Introduced in 2022, Dexcom U was created to provide collegiate athletes who have diabetes with the tools, support, and platform necessary to excel both on and off the field. With its mission firmly rooted in highlighting the capabilities of individuals with diabetes, the program has been lauded for its innovation and impact. For the 2024 season, Dexcom is thrilled to welcome a new cadre of athletes from various prestigious institutions, including Alabama AandM. These athletes are not just competitors in their respective sports; they are trailblazers representing resilience, determination, and the strength to overcome the challenges posed by diabetes.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
